Archive | Clinical Trials

New targeted therapy schedule could keep melanoma at bay

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30.

Read the full story

Posted in Melanoma In The News, Clinical Trials

BRAF/MEK inhibitor therapy a preferred option for metastatic melanoma

Combination therapy with BRAF and MEK inhibitors can confer long-term survival for patients with low-burden metastatic melanoma and should be a preferred treatment option, according to a presenter at HemOnc Today New York.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Nivolumab With/Without Ipilimumab Active in Melanoma Brain Metastases

Nivolumab alone or with ipilimumab produces durable, clinical responses among patients with previously untreated brain metastases from primary melanoma, according to a study published in The Lancet Oncology.

Read the full story

Posted in Melanoma In The News, Clinical Trials

T-VEC Injections Safe in Patients with Advanced-Stage Liver Metastases

According to early results of an ongoing early-phase study presented at the 2018 Society of Interventional Radiology Annual Scientific Meeting, image-guided injections of talimogene laherparepvec immunotherapy (T-VEC, Imylgic) were deemed tolerable in patients with advanced-stage liver metastases.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories